Ilya Rachman
More actions
| Nationality | American |
|---|---|
| Occupation | Physician-scientist, biotechnology executive, cell biologist |
| Years active | 2012–present |
| Known for | Founder, Chairman, CEO and Chief Scientific Officer of Immix Biopharma |
| Education | University of Iowa; University of Illinois Chicago; University of California, Los Angeles |
Ilya M. Rachman is an American physician-scientist, biotechnology executive and cell biologist. He is the founder, chairman and chief executive officer of Immix Biopharma, Inc., a biotechnology company established in 2012. He has also served as the company's chief scientific officer since March 2026.
Early life and background
Rachman received his undergraduate education at the University of Iowa and is based in Los Angeles, California, United States. His professional interests developed through his experience in clinical medicine and the treatment of patients.
His work with patients facing limited therapeutic options influenced his interest in developing new treatments. This experience contributed to his transition from clinical practice toward biotechnology and therapeutic research.
Education and medical training
Rachman earned a Bachelor of Science degree from the University of Iowa. He subsequently completed a joint Doctor of Medicine and Doctor of Philosophy degree at the University of Illinois Chicago, where his research focused on neuroendocrinology.
He later received an Executive Master of Business Administration from the University of California, Los Angeles. He also undertook medical and research training at UCLA Health.
Medical and scientific career
Rachman began his professional career in medicine and subsequently worked as a physician-scientist at Cedars-Sinai Medical Center and UCLA Health. His experience encompassed clinical medicine, medical research, neuroendocrinology and experimental oncology.
Before establishing Immix Biopharma, he founded a clinical research organization involved in conducting pharmaceutical clinical trials, including Phase III and Phase IV studies.
His scientific work includes research in cell biology and neuroendocrinology. He has also been identified as an inventor on patents associated with Immix Biopharma.
Founding of Immix Biopharma
In 2012, Rachman founded Immix Biopharma, Inc., a biotechnology company focused on therapeutic development. The company's initial activities were associated with oncology before expanding into advanced cell therapies and immune-based treatments.
He has served as chairman and chief executive officer since the company's establishment. In March 2026, he additionally assumed the position of chief scientific officer.
In these roles, Rachman oversees corporate operations, scientific strategy and the company's research and development activities.
Immix Biopharma and AL amyloidosis
Under Rachman's leadership, Immix Biopharma has pursued the development of treatments involving cell therapies and other approaches targeting the immune system.
One of the company's principal therapeutic areas is AL amyloidosis, a disease in which abnormal plasma cells produce light chains that can accumulate in organs such as the heart, kidneys and liver.
NXC-201
Immix Biopharma's lead therapeutic candidate is NXC-201, a BCMA-targeted chimeric antigen receptor T-cell therapy being developed for patients with relapsed or refractory AL amyloidosis.
The treatment incorporates a proprietary CD3ζ signaling domain, CD8 hinge and binder design intended to limit nonspecific immune activation. Its development focuses on targeting the plasma cells responsible for producing harmful light chains.
Rachman oversees the company's scientific direction as it advances research into NXC-201 and other cell-based therapeutic approaches.
Leadership and business experience
Through his leadership at Immix Biopharma, Rachman has gained experience in corporate management, scientific development and engagement with investors, business partners, boards and regulatory stakeholders.
His professional background includes:
- Clinical medicine
- Physician-scientist research
- Cell biology
- Neuroendocrinology
- Experimental oncology
- Clinical trial development
- Biotechnology management
- Scientific strategy
- Public-company operations
His responsibilities combine scientific oversight with the management and development of a biotechnology business.
Research and publications
Rachman's research background includes neuroendocrinology, experimental oncology and clinical research. His scientific publications are listed through his Google Scholar profile.
He has also been named as an inventor on patents associated with Immix Biopharma.